Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

• Published in: International Journal of Obesity 2006-12, Vol.30 (12), p.1729-1736
• Main Authors: Wynne, K, Park, A.J, Small, C.J, Meeran, K, Ghatei, M.A, Frost, G.S, Bloom, S.R
• Format: Article
• Language: English
• Subjects: Adult; adults; Anti-Obesity Agents - adverse effects; Anti-Obesity Agents - blood; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Biological and medical sciences; Blood Pressure - drug effects; Body Mass Index; Body weight; Calories; Calorimetry; Care and treatment; Cross-Over Studies; diet; Double-Blind Method; Drug dosages; drug therapy; Energy; Energy balance; energy expenditure; energy intake; Energy Intake - drug effects; Energy Metabolism - drug effects; Epidemiology; Exercise; Feeding. Feeding behavior; Female; food intake; Fundamental and applied biological sciences. Psychology; General aspects; Health aspects; Health Promotion and Disease Prevention; Heart rate; Heart Rate - drug effects; Humans; Injections, Subcutaneous; Insulin - blood; Internal Medicine; Male; Medical sciences; Medicine; Medicine & Public Health; men; Metabolic Diseases; Metabolism; Middle Aged; movement; Obesity; Obesity - blood; Obesity - drug therapy; Obesity - physiopathology; original-article; Overweight; Overweight - drug effects; oxyntomodulin; Oxyntomodulin - adverse effects; Oxyntomodulin - blood; Oxyntomodulin - pharmacology; Oxyntomodulin - therapeutic use; palatability; Peptide hormones; Peptides; physical activity; Physical fitness; Public Health; randomized clinical trials; Self Administration; subcutaneous injection; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Weight control; women
• ISSN: 0307-0565; 1476-5497
• DOI: 10.1038/sj.ijo.0803344

Background: Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy. Objective: To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers. Design: Randomized double-blind controlled cross-over trial. Setting: Community and hospital-based. Participants: Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m2). All volunteers completed the study protocol. Interventions: Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen. Measurements: (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal. Results: Oxyntomodulin administration reduced energy intake at the study meal by 12829 kcal (P=0.0006) or 17.35.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143109 kcal/day or 26.29.9% (P=0.0221); total energy expenditure by 9.44.8% (P=0.0454) and physical activity level by 9.54.6% (P=0.0495). A reduction in body weight of 0.50.2% was observed during the oxyntomodulin administration period (P=0.0232). Conclusion: Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.